CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 32 enrolled
Drug / intervention
Wellbutrin +1 moredrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓Diagnosed with depression
  • ✓Currently treated with SSRI
Key exclusion· 6
  • ✕Bipolar disorder
  • ✕Prior or current SNRI or bupropion treatment
  • ✕Treatment-resistant depression
  • ✕Seizure disorder

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00125957
NCT00125957Phase 3Completed
CompareCT.gov

The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression

Mclean Hospital·interventional·Posted Aug 2, 2005·Updated Aug 6, 2014

In Brief

A Phase 3 clinical trial evaluating Wellbutrin and Placebo for Depression and 2 related conditions. Completed, enrolled 32 participants across 1 site.

Detailed Summary

Many people with depression are treated with a serotonin-specific reuptake inhibitor anti-depressant (SSRI) and feel 'better'. Although many people feel 'better', they do not feel completely 'well'. Often, individuals continue to complain of cognitive problems such as lack of attention, diminished motivation, and impaired problem-solving. This study looks at whether residual and cognitive symptoms of depression in individuals are affected by the addition of Wellbutrin (bupropion).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Major Depressive Disorder, Unipolar Depression
CountriesUnited States
CollaboratorsNational Association for Research on Schizophrenia and Affective Disorders.

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2, 2005
Enrollment StartAug 1, 2005
Primary CompletionJan 1, 2010
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 20.9 years ago

Interventions

Wellbutrindrug

Placebodrug